4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile Chemical Properties

Boiling point:

459.3±45.0 °C(Predicted)

Density 

1.26±0.1 g/cm3(Predicted)

storage temp. 

2-8°C

4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile Usage And Synthesis

Uses

4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile is an impurity of Erlotinib (E625008), a EGFR-targeted drug in the treatment of non-small cell lung cancer. EGFR small tyrosine kinase inhibitor that shows most substantial effect on tumor growth inhibition and animal survival.

Synthesis

The general procedure for the synthesis of 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile from 3,4-bis(2-methoxyethoxy)benzonitrile was as follows: 1) Nitration reaction: 200g of 3,4-bis(2-methoxyethoxy)benzonitrile was dissolved in 3L of glacial acetic acid to prepare feedstock I. Concentrated sulfuric acid and concentrated nitric acid were used as feedstock II and feedstock III, respectively. the flow rate was adjusted by a flow pump so that the flow rate of feedstock I was 20 ml/min, that of feedstock II was 10 ml/min, and that of feedstock III was 6 ml/min. the flow rate was adjusted by a flow pump so that the flow rate of feedstock II was 10 ml/min, and the flow rate of feedstock III was 6 ml/min. It was ensured that the molar ratio of HNO3 to 3,4-bis(2-methoxyethoxy)benzonitrile was 1:1.5, and the mass ratio of concentrated nitric acid to concentrated sulfuric acid was 1:4. The reaction temperature was set at 60 °C, and the reaction residence time was set at 60 seconds. The temperature of the cooling module was set to 20 °C. The reaction solution from the outlet of the cooling module was collected and the glacial acetic acid was recovered by distillation under reduced pressure. The residue was added to 1.2 L of water and extracted twice with 1 L of ethyl acetate. The organic phases were combined, washed to neutrality with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate and evaporated. 215.21 g of 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile was obtained with 90.58% yield and 98.95% purity.

References

[1] Patent: CN108358798, 2018, A. Location in patent: Paragraph 0055; 0065; 0075; 0085; 0094-0099; 0102
[2] Patent: WO2007/138612, 2007, A2. Location in patent: Page/Page column 10
[3] Patent: WO2007/138613, 2007, A2. Location in patent: Page/Page column 11-12
[4] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 3, p. 909 - 914
[5] Heterocycles, 2007, vol. 71, # 1, p. 39 - 48

4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(236750-65-5)Related Product Information

• 4-Quinazolinamine,N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-,hydrochloride(1:1)
• Erlotinib Impurity 67
• Erlotinib Imp.9
• Erlotinib iMpurity 2
• 2-Amino-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester hydrochloride
• 4-QuinazolinaMine, 7-(2-chloroethoxy)-N-(3-ethynylphenyl)-6-(2-Methoxyethoxy)-
• 3-Ethynylaniline
• 6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine
• 4-Methyl Erlotinib Hydrochloride
• 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-hydroxyethoxy)quinazoline
• Erlotinib Impurity 35
• 4-Quinazolinamine,N-(3-ethylphenyl)-6,7-bis(2-methoxyethoxy)-
• Erlotinib iMpurity B
• Erlotinib Impurity 20
• Erlotinib iMpurity
• Desmethyl Erlotinib Acetate
• Erlotinib IMpurity C
• 2,3,5-Trimethylpyridine-1-Oxide